The DOI matches its Crossref record; 177 of the 181 references it cites were found in a registry or an index.
American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update
Abstract
OBJECTIVE This consensus statement provides (1) visual guidance in concise graphic algorithms to assist with clinical decision-making of health care professionals in the management of persons with type 2 diabetes mellitus to improve patient care and (2) a summary of details to support the visual guidance found in each algorithm. METHODS The American Association of Clinical Endocrinology (AACE) selected a task force of medical experts who updated the 2020 AACE Comprehensive Type 2 Diabetes Management Algorithm based on the 2022 AACE Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan and consensus of task force authors. RESULTS This algorithm for management of persons with type 2 diabetes includes 11 distinct sections: (1) Principles for the Management of Type 2 Diabetes; (2) Complications-Centric Model for the Care of Persons with Overweight/Obesity; (3) Prediabetes Algorithm; (4) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Dyslipidemia; (5) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Hypertension; (6) Complications-Centric Algorithm for Glycemic Control; (7) Glucose-Centric Algorithm for Glycemic Control; (8) Algorithm for Adding/Intensifying Insulin; (9) Profiles of Antihyperglycemic Medications; (10) Profiles of Weight-Loss Medications (new); and (11) Vaccine Recommendations for Persons with Diabetes Mellitus (new), which summarizes recommendations from the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention. CONCLUSIONS Aligning with the 2022 AACE diabetes guideline update, this 2023 diabetes algorithm update emphasizes lifestyle modification and treatment of overweight/obesity as key pillars in the management of prediabetes and diabetes mellitus and highlights the importance of appropriate management of atherosclerotic risk factors of dyslipidemia and hypertension. One notable new theme is an emphasis on a complication-centric approach, beyond glucose levels, to frame decisions regarding first-line pharmacologic choices for the treatment of persons with diabetes. The algorithm also includes access/cost of medications as factors related to health equity to consider in clinical decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While recent guidelines call for continuous glucose monitoring (CGM) use for all who require insulin, regardless of diabetes type (7), there is also evidence that patients may not know how to interpret what to do with the CGM data (6, 8, 9).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [7]
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Research works printed but not linked: 2
- 2008, Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545
- Mechanick, 2019, Endocr Pract, 25, 1346
Cited by
Sorted by citations
Items 201–300 of 373
Long-Term Care of the Liver Transplant Recipient
Scheinberg, A. R., Martin, P., & Turkeltaub, J. A. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.12.007 · Cited by 2
A brief approach to hypertension in type 2 diabetes mellitus
Güneş, Y. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101422 · Cited by 5
Foundations of Pediatric Lifestyle Medicine
Gaínza‐Lein, M. (2025) · Children · doi:10.3390/children12030304 · Cited by 3
“Given these benefits, several leading medical organizations, including the American College of Lifestyle Medicine, have endorsed a predominantly plant-based diet [1,56], as well as the U.S. dietary guidelines for diabetes [57], cardiovascular prevention [58], and cancer [59].”
Kostopoulou, K., Lekka, D., Pnevmatikakis, A., Angelova, N., Stafylas, P. C., Tamouridis, S., Bargiota, Α., & Kyriazakos, S. A. (2025) · JMIR Formative Research · doi:10.2196/73807 · Cited by 3
“…how to monitor blood glucose and how to take proper medication [21] and an article that offered tips and guidance for better sleep patterns [22]) • 5.1, 5.3, and 5.6: information about health, social, environmental, and emotional consequences (small text tips were delivered as messages…”
InfluentialLiu, D., Chen, X., Wang, Q., Pan, X., Wei, X., Wang, B., Wang, Y., Xue, X., & Lu, C. (2025) · Precision medication. · doi:10.1016/j.prmedi.2025.100035 · Cited by 2
Lee, A. K., Lipska, K. J., Callahan, K. E., Raphael, E., & Lee, S. J. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-004929 · Cited by 2
Megawati, G., Syahruddin, S. S., Tjandra, W., Kusumawati, M., Herawati, D. M. D., Gurnida, D. A., & Musfiroh, I. (2023) · Nutrients · doi:10.3390/nu15183904 · Cited by 2
“These interventions play a pivotal role in achieving personalized targets for glycemic control, blood pressure regulation, and lipid profiles [6,7].”
BackgroundComments on the 2023 ESC guidelines on cardiovascular disease in patients with diabetes
SEC Working Group for the 2023 ESC Guidelines on cardiovascular disease in patients with diabetes and SEC Guidelines Committee (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.11.005 · Cited by 2
Ruan, Z., Chen, X., Song, M., Jia, R., Luo, H., Ung, C. O. L., & Hu, H. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s483065 · Cited by 2
Tillman, J. B., Beck, R. W., Polonsky, W. H., Calhoun, P., Mouse, T., Bailey, R., Jacoby, J., Nandan, R., Sheikh, F. N., & Malone, J. K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae778 · Cited by 1
Vázquez, L. A., Tofé, S., Bellido, D., Botella-Serrano, M., Soto-González, A., Mezquita‐Raya, P., Delgado, E., Fajardo, C., Morales, C., Causanilles, A., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01587-6 · Cited by 2
Wisseh, C., Adinkrah, E. K., Opara, L., Melone, S., Udott, E., Bazargan, M., & Shaheen, M. A. (2024) · Pharmacy · doi:10.3390/pharmacy12030083 · Cited by 1
“…evidence has been promising for two of these drug classes, as SGLT2i and GLP-1RA have been recommended in clinical guidelines as first-line agents, with or without metformin, for concomitant cardiovascular risk reduction in patients with diabetes and compelling cardio-vascular conditions [38,39].”
BackgroundGuía latinoamericana de recomendaciones al egreso de un síndrome coronario agudo
Ponte-Negretti, C. I., Zaidel, E. J., López-Santi, R., Múnera, A. G., Bryce, A., M, S. N., Espinoza, J., Gaibor, J. C., Valcárcel, Y., Antonio, C. D., et al. (2024) · Archivos de cardiología de México · doi:10.24875/acm.m24000096 · Cited by 4
Risk factors for fasting blood glucose control in middle-aged and elderly type 2 diabetes patients
Kuang, N.-Y., Ye, H., Chen, J.-P., Li, H., & Tang, N. (2024) · Medicine · doi:10.1097/md.0000000000039322 · Cited by 2
“A meta-analysis in 2023 suggested [35] that the most widely used lipid-lowering statin drugs slightly but significantly increase blood glucose levels and affect blood glucose control; although the diabetogenic effect of statins is not fully understood, some potential mechanisms have been proposed,…”
BackgroundStoltenberg, C. W., Hangaard, S., Hejlesen, O. K., Kronborg, T., Vestergaard, P., & Jensen, M. H. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241280096 · Cited by 3
“3,8 Insulin therapy is often initiated with long-acting options in people with type 2 diabetes; however, many will eventually require additional fast-acting insulin before or at the time of meals to reach glycemic target.”
Painful polyneuropathy in people with diabetes
Allen, J. W. (2024) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000241 · Cited by 1
Management of Hypertension in Patients with Diabetes
Brinkman, A. (2024) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2024.08.002 · Cited by 1
Wang, Y., Ren, J., Chai, X., Wang, Y., Lu, Z., Dong, J., Guo, X., Yin, X., Zhang, J., Tang, J., et al. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01796-x · Cited by 2
Melo, P., Freitas, P., Carvalho, R., Carvalho, F. S., Jordão, S., do Vale, S., Carvalho, D. M., Abreu, S., Barros, L., de Castro, J. J., et al. (2024) · Endocrinology Insights · doi:10.1159/000541873 · Cited by 2
“These recommendations are in line with the ADA and AACE recommendations [32, 35].”
InfluentialBarber, T., Neumiller, J. J., Fravel, M. A., Page, R. L., II, & Tuttle, K. R. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf045 · Cited by 1
Beta-cell preservation in T2DM using a pathophysiologic approach
Papatheodorou, K., & Shubrook, J. H. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2494502 · Cited by 2
“These factors worsen insulin resistance and increase beta-cell secretory demand [20].”
Alicic, R. Z., & Neumiller, J. J. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.003 · Cited by 1
López-Saldarriaga, C., & Briceño, J. C. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01494-x · Cited by 1
Meta-analysis of TCF7L2 and SLC30A8 gene polymorphisms concerning type 2 diabetes risk
Muruganantham, J. K., & Veerabathiran, R. (2025) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-025-00464-3 · Cited by 1
Brady, V. J., Akyirem, S., & Padhye, N. S. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.05.011 · Cited by 1
Oral FcRn-targeted insulin: Challenges and current strategies
Aghakhani, A., Bahreini, F., Uversky, V. N., & Rezaei, N. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107214 · Cited by 1
Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes Mellitus
Sethi, B. K., Chowdhury, S., Jain, S. M., Zargar, A. H., Chadha, M. D., Bhattacharyya, A., Shaikh, S. S., Makkar, B. M., Chawla, M. S., Kalra, P., et al. (2025) · Cureus · doi:10.7759/cureus.87002 · Cited by 1
“Image credit: Dr. Sanjay Jain Recommendations by guidelines: The American Association of Clinical Endocrinology (AACE) recommends initiating combination therapy for patients with an HbA1c level above 7.5% [42].”
InfluentialHypokalemia Requiring Hospitalization After Taking Semaglutide Injections
Grennan, K., Singh, D., Chindris, A.-M., & Wilson, J. R. (2025) · Cureus · doi:10.7759/cureus.87382 · Cited by 1
“Similarly, the American Association of Clinical Endocrinology's (AACE) 2023 Consensus Statement on type 2 diabetes management emphasizes that GLP-1RAs are preferred medications in patients who are classified as overweight or obese, have a risk of hypoglycemia, and/or have severe hyperglycemia [4].”
Metabolic syndrome in reproductive age: A cross-sectional study
Aringazina, R. A., Zholdassova, N., Berdesheva, G., Nurgaliyeva, Z., Kurmanalina, G. L., Zhanalina, B., & Sharlovych, Z. (2025) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.18502/ijrm.v23i5.19262 · Cited by 1
“The sex hormones (estradiol and testosterone) levels were determined by enzyme-linked immunosorbent assay to analyze the fertile state under the American Association of Clinical Endocrinologists guidelines (25).”
Evans, M., Lewis, E. D., Joseph, A., Crowley, D., & Guthrie, N. (2025) · Journal of Food Science and Technology · doi:10.1007/s13197-025-06414-9 · Cited by 1
“Despite treatment with existing medical algorithms for T2DM management (Samson et al. 2023), controlling it has been challenging.”
Cokro, F., Sauriasari, R., Tahapary, D. L., Setiawan, H., Tricaesario, C., Hidayati, N., & Soegondo, S. (2025) · F1000Research · doi:10.12688/f1000research.163923.3 · Cited by 1
Kamrul-Hasan, A. B. M., Pappachan, J. M., Nagendra, L., Akter, N., Jena, S., Dutta, D., & Nair, S. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i10.111230 · Cited by 2
Mykhaylenko, O. Y., & Єлізарова, О. Т. (2025) · Galician Medical Journal · doi:10.21802/e-gmj2025-a27 · Cited by 1
Saboo, B., Kalra, P., Majumdar, S., Phatak, S., Deka, N., Kadam, Y., Kotru, S., Shivane, V. K., Nanditha, A., Tyagi, P., et al. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_29_25 · Cited by 1
Wang, J., Wei, Y., Shi, P., Ji, C. F., Xu, L., Kong, Y., Ye, J., Wang, X., Xu, J., & Wang, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1690339 · Cited by 1
Wang, Y., Zhou, W., Zhou, Q., Du, C., Tang, Y., & Zhu, K.-F. (2025) · Cardiovascular Therapeutics · doi:10.1155/cdr/9927583 · Cited by 1
“Diagnoses of hypertension and Type 2 diabetes mellitus (T2DM) in subjects were made according to the guidelines [6, 7] or current use of medications.”
Erande, S. G., Agrawal, M., Gulati, S., Jagtap, N., Kumar, N. S. P., Kapoor, V. K., Bhushan, S., Gadkari, R., Jadhav, M., CHOUDHARI, S. Y., et al. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00244-6 · Cited by 1
“Hence, major diabetes guidelines, ADA, EASD, AACE and others recommend the use of SGLT2i + DPP4i combination for effective diabetes and GV control [25–27].”
Oh, Y. E., Kim, T., Ah, S., Park, H. J., Min, Y. W., Lee, H., Lee, J. H., Rhee, P., Kim, J. J., & Min, B. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.112694 · Cited by 2
Sun, G., Wen, Y., Han, X., Wang, Q., Wang, Y., Ma, H., Sun, X., Zhai, Y. Z., Wen, Y., & Han, X. (2025) · Medicine · doi:10.1097/md.0000000000046261 · Cited by 1
“[20] Despite progress in reducing mortality, ASDR demonstrates an alarming global upward trend, particularly in high-SDI regions.”
Sanyal, D., & RoyChaudhuri, S. (2025) · Cureus · doi:10.7759/cureus.100108 · Cited by 1
“Managing T2DM involves not only maintaining glycemic control but also preventing and treating comorbidities and complications such as cardiovascular disease (CVD) and CKD [5].”
InfluentialGangopadhyay, K. K., Sharma, A. K., Kumar, A., Mehta, A., Mohan, J. C., Malige, M., Kumar, R. B., Mittal, R., Singh, S. K., Singh, S. K., et al. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20254400 · Cited by 1
Sciscent, B. Y., Eberly, H. W., Lorenz, F. J., Goldrich, D. Y., Goyal, N., & Goldenberg, D. (2026) · OTO Open · doi:10.1002/oto2.70188 · Cited by 2
Sulthana, M. T., Alagarsamy, V., Solomon, V. R., Islam, M. M., Dhanwar, S., Harika, G., Sabarees, G., & Murugesan, S. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100226 · Cited by 1
Ma, Y., Lin, Y., Ding, X., & Peng, Y. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70176 · Cited by 1
Falcetta, P., Zilich, R., Baccetti, F., Baronti, W., Morviducci, L., Musacchio, N., Marco Muselli, B., Ozzello, A., Pisani, F., Rossi, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70648 · Cited by 1
“For these reasons, current guidelines recommend follow-up at 3–6 months after the diagnosis and then at least annually [31, 32].”
Rontoyanni, V. G., Finnerty, C. C., & Murton, A. J. (2026) · Burns · doi:10.1016/j.burns.2026.107979 · Cited by 1
Song, B. G., Kim, T., Kim, B. S., Han, K., & Min, B. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101776 · Cited by 1
Chen, Z., Cheng, R., Wang, H., & Hu, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71083 · Cited by 2
Wang, M. D., Liu, T., & Zhao, B. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1846454 · Cited by 1
“Although optimal control of glycemia, serum lipids, and blood pressure can reduce the risk of microvascular complications (4), pharmacological strategies speci fi cally targeting diabetic microangiopathy remain limited (5).”
Cokro, F., Sauriasari, R., Tahapary, D. L., Setiawan, H., Tricaesario, C., Hidayati, N., Djauhari, W., Tandradynata, J., & Soegondo, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0353564 · Cited by 1
Diagnosis and treatment of prediabetes as prevention of type 2 diabetes: A review
Petunina, N. A., Martirosian, N. S., Викторович, Х. М., Zhutaeva, M. A., Shaposhnikova, A. A., Karpenko, E. V., & Abdulganieva, Z. A. (2023) · Consilium Medicum · doi:10.26442/20751753.2023.4.202312 · Cited by 1
“Поэтому для пациентов с предиабетом, которые имеют избыточную массу тела/ожирение, рекомендовано создать дефицит калорий в объеме 500–1000 ккал в день в контексте здорового питания [12].”
InfluentialShyshkan-Shyshova, К. О., Zinych, О. В., Кushnareva, N. M., Ковальчук, А., & Prybyla, О. В. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.7.2023.1330 · Cited by 1
Demidova, T. Y., Titova, V. V., & Скуридина, Д. В. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-4-23 · Cited by 1
Comentarios a la guía ESC 2023 sobre enfermedad cardiovascular en pacientes con diabetes
de la SEC, G. D. T. D. L. S. P. L. G. E. 2. S. E. C. E. P. C. D. Y. C. D. G. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.11.006 · Cited by 1
Ayat, P., Sawassnajjar, D., Alkaissi, H. R., Gill, H., Otey, J., AlFaraj, M., & McFarlane, S. I. (2024) · Cureus · doi:10.7759/cureus.63061 · Cited by 1
“Several treatment options are available and approved for diabetes, yet there are no FDA-approved agents for prediabetes, and thus, lifestyle modification remains the mainstay of treatment [10].”
BackgroundBaalmann, A. R., Norton, M. C., Gadbois‐Mincks, N. R., Ofei‐Dodoo, S., & Presnell, E. N. (2024) · Obesity Science & Practice · doi:10.1002/osp4.70011 · Cited by 1
Dong, H., Li, X., Gu, Q.-X., Ma, C., Yuan, M., Wang, Z.-Z., Su, J., Xu, L., Chen, C., Ebule, Q., et al. (2024) · Biomarkers in Medicine · doi:10.1080/17520363.2024.2432309 · Cited by 1
Matz, L. M., Shah, N. S., Porterfield, L. R., Stuyck, O. M., Jochum, M. D., Kayed, R., Taglialatela, G., Urban, R. J., & Buffington, S. A. (2024) · Frontiers in Microbiomes · doi:10.3389/frmbi.2024.1456642 · Cited by 1
Agarwal, P. K., Bhushan, D., Bhate, A. S., Naik, S., Adwani, S., KUSHWAHA, J., Bhushan, S., Mane, A., Gadkari, R., CHOUDHARI, S. Y., et al. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00210-8 · Cited by 1
Neumiller, J. J. (2025) · Diabetes Spectrum · doi:10.2337/ds24-0079 · Cited by 1
Trujillo, D. A. V., Bautista, L. Y. R., Espinosa, C. M., del Castillo, S. S. F., Corredor-Rengifo, D., Aristizábal-Colorado, D., & Abreu-Lomba, A. (2025) · Cureus · doi:10.7759/cureus.77725 · Cited by 2
A Consensus Report on Management of Type 2 Diabetes Mellitus in Iran
Esteghamati, A., Malek, M., Hosseinpanah, F., Hadaegh, F., Afkhami‐Ardekani, M., Meybodi, H. R. A., Dabbaghmanesh, M. H., Ghaemi, F., Jahed, S. A., Kalbasi, S., et al. (2024) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.39.13 · Cited by 1
Florez, H. J., Correa, R. R., & Valencia, W. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2587 · Cited by 2
Self-citationRosario, N., Hunger, C., Pettijohn, A., Whaley, K., Pabon, A., Hohl, V., Asias-Dinh, B. D., Gee, J. S., & Wollen, J. T. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251327318 · Cited by 1
Stewart, M. P., Loera, L. J., Onwukwe, B., Reveles, K. R., & Lin, K. P. (2025) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2025.102493 · Cited by 2
Choudhry, N. K., Priyadarshini, S., Swamy, J., & Mehta, M. (2024) · medRxiv · doi:10.1101/2024.10.20.24315560 · Cited by 1
AACE Endocrinology and Diabetes: An Exciting New Endocrinology Journal
Tangpricha, V. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.04.003 · Cited by 1
Editorial for July/August Issue of AACE Clinical Case Reports
Jasim, S., & McGill, J. B. (2023) · AACE Clinical Case Reports · doi:10.1016/j.aace.2023.06.005
Prediabetes: A Platform for Prevention of Diabetes
Kalra, S., Sahay, R. K., & Bhattacharya, S. (2023) · Asian Journal of Diabetology · doi:10.59793/ajd.v24i2.533
Primary Care Medicine - Theory and Practice
Çakmur, H. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.111122 · Cited by 1
Шамхалова, М. Ш., & Sukhareva, O. Y. (2023) · Diabetes Mellitus · doi:10.14341/dm13079 · Cited by 1
Cambios en el control glucémico antes y después de la cuarentena por la COVID-19
Murillo-Valle, J. R., & Meza-Ponte, J. L. (2023) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2023.403.12830
“…complications (2) ; likewise, all guidelines recommend an individual and multifactorial approach to the different cardiovascular risk factors; for example, healthy lifestyle changes, emotional balance and appropriate medication under medical supervision are the basis for adequate control (3,4) .”
BackgroundA Patient-Centered Management of Patients with Diabetes Type 2: Are All Diabetic Patients the Same?
Bosnić, Z., Šojat, D., Kurevija, T., Pirić, M., Božinović, R., Miletić, M., Feldi, I., Bačun, T., Žagar, S., & Majnarić, L. T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003106
Kim, S.-S., & Kim, H. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm14010042
“The American Diabetes Association (ADA) and Korean Diabetes Association (KDA) recommend assessing comorbidities before prescribing DM drugs [9,10].”
BackgroundManagement of type 2 diabetes after metabolic bariatric surgery
Tham, K. W., & Lee, P. C. (2023) · Mini-invasive Surgery · doi:10.20517/2574-1225.2023.80
Nutrition counsellors’ recommended eating patterns for individuals with type 2 diabetes in the USA
KHOSROVANEH, K. L., Hisamatsu, R., Reiss, J., RAU, J., Oshman, L. D., Diez, H. L., Lee, J. M., Aikens, J. E., Richardson, C. R., & Hafez, D. (2024) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2023-000845 · Cited by 1
“Respondents who recommended low-carbohydrate and/or very low-carbohydrate eating pattern(s) to their patients were also asked to report their perceived benefits and concerns about those eating pattern(s) (figure 1).”
BackgroundMetabolic background as the basis for comorbidity in patients with type 2 diabetes mellitus
Demidova, T. Y., & Омариевна, У. Ф. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-137
Cardiovascular Disease Risk and Risk Reduction Strategies in Diabetes Mellitus
Wilson, D. P., Hamilton, L., & Maki, K. C. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_14
Ghosh, S. K., WANGNOO, S. K., Chittawar, S., Damodharan, S., Kadam, Y., Kalra, P., Kumar, K. P. S., Periyandavar, I., Sharma, S. K., & Zargar, A. H. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem946
Çimen, İ. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2667-2
“Diabetes significantly increases the occurrence and adverse prognosis of coronary heart disease, with consensus pointing towards its treatment focusing on the prevention and management of diabetes complications (Samson et al., 2023).”
Kalra, P., Dharmalingam, M., Kubba, S. V., Bhojwani, H. R., & Jain, S. (2024) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20241968
Арутюнов, Г. П., Галстян, Г. Р., Т., Ю. Д., Dzgoeva, F. K., Владиславович, Е. М., В., Ю. К., Г., А. К., Д., В. Л., И., В. С., Ф., Е. Ш., et al. (2024) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2024.02.0001 · Cited by 1
Paradigm shift in diabetes care: Glucose-centric to cardio-metabolicrenal approach
Rameshkumar, T., & Katulanda, P. (2022) · Ceylon Journal of Medical Science · doi:10.4038/cjms.v59i1.5065
Ji, C. X., Blecker, S., Oberst, M., Shih, M., Horwitz, L. I., & Sontag, D. A. (2024) · medRxiv · doi:10.1101/2024.09.19.24313155
Hau, N. V. V., Bang, N. V., Xuan, N. T., Linh, P. N. T., Thoi, N. T. N., Trang, V. T., Trung, P. M., Chi, L. V., & Thuy, N. H. (2024) · Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế · doi:10.38103/jcmhch.16.8.12
Cai, X., Ji, L., Yuan, M., Ma, J., Bian, F., Li, S., Pang, W., Yan, S., Zhou, H., Hou, M., et al. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101197
Use of Automated Machine Learning to Detect Undiagnosed Diabetes in U.S. Adults (Preprint)Preprint
Ji, M., & An, R. (2024) · doi:10.2196/preprints.68260
Evaluating the Impact of Integrating Ayurveda with Allopathy in Diabetes Management: A Meta-Analysis
Murugaiyan, V., Samuel, K. S. K. J., Kalaiselvan, S., & Marokey, A. S. (2024) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3310
Karara, M. W., Okalebo, F., Karimi, P. N., & Opanga, S. A. (2025) · Journal of Advances in Medical and Pharmaceutical Sciences · doi:10.9734/jamps/2025/v27i1742
Cai, J., Li, P., Li, W., Hao, X., Li, S., & Zhu, T. (2024) · doi:10.2196/preprints.70475
Mbaye, M. N., Anzouan-Kacou, J.-B., Tia, W. M., Bamba, D., Dione, J.-M. A., Kâ, E. H. F., Kane, A. D., Ngaïdé, A. A., Niang, A., Moke-Bédji, L. O., et al. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.01.001
Zhang, J., Li, A., Quan, J., Wu, J. J., Cai, H., Ding, Y., Tang, J., Ma, X., & Zhang, J. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01690-8
“…for instance, to achieve HbA1c levels ≤ 6.5% or as close to normal as possible, was advocated by the American Association of Clinical Endocrinologists Consensus for most patients and it was also recommended in the CDS guideline for some patients in better overall health conditions [11, 13].”
InfluentialAbordaje racional de la prediabetes
Cuenca, A. M. C., Flores, A. E., Moore, J. R., Coman, A. C., & Hernández, M. L. (2025) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2024.05.010
Inhibidores del cotransportador de sodio-glucosa tipo 2
Martínez, E., & Fernández, I. V. (2025) · Actualización en Medicina de Familia · doi:10.55783/amf.210205
3. Blood glucose-lowering therapies – Non-insulin options for type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112147
Digital Decision Support for Perioperative Care of Patients With Type 2 Diabetes: A Call to Action
Cai, J., Li, P., Li, W., Hao, X., Li, S., & Zhu, T. (2025) · JMIR Diabetes · doi:10.2196/70475
“As the American Association of Clinical Endocrinology stated in their 2023 Type 2 Diabetes Management Algorithm [16], personalized care is emphasized through evidence-based tools such as continuous glucose monitoring and automated insulin dosing systems.”
Sobczak, C., Oser, S. M., Warman, M., Daffron, A., Buss, D., Wettergreen, S. A., Oser, T. K., Parascando, J. A., & Jortberg, B. T. (2025) · ADCES in Practice · doi:10.1177/2633559x251328956
Pulipati, V. P., Zilbermint, M. F., & Patel, S. B. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.009
Prevalence of Heart Failure With Type 1 Diabetes and Type 2 Diabetes Among US Adults
Chetty, A. K., & Chen, A. S. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.019
Clinical pharmacist roles in a virtual continuous glucose monitor initiation service
Wettergreen, S. A., Sobczak, C., Jortberg, B. T., Oser, S. M., Buss, D., Parascando, J. A., Daffron, A., & Oser, T. K. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70046
“21 – 25 Despite the clinical, behavioral, and psychosocial benefits of CGM in people with type 1 and type 2 diabetes, access is relatively limited outside of endocrinology practices.”
Metadata
- Authors
- Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., Umpierrez, G. E., & Valencia, W. M.
- Affiliations
- Mayo Clinic (US)
- Grady Memorial Hospital (US)
- Ochsner Health System (US)
- Indiana University Columbus (US)
- University of Miami (US)
- University of Washington (US)
- Emory University (US)
- University of Nevada, Las Vegas (US)
- Maine Medical Center (US)
- Cleveland Clinic (US)
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 29
- Issue
- 5
- Pages
- 305-340
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W4372214811
- Semantic Scholar
- 066a5bccabf1b093084ed77c43509daa1c94c321
- Cited by
- 375
- References
- 181
- Citations by year
- 2026: 62 · 2025: 150 · 2024: 124 · 2023: 38
- FWCI
- 76.07
- Type
- journal article
- Language
- en
- Update notices
- Open access
- closed
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK123384)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, prediabetes, glycemic control, dyslipidemia, hypertension, insulin intensification, antihyperglycemic medications, anti-obesity drugs, obesity, lifestyle modification, health equity
- MeSH terms
- Endocrinologists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Endocrinology, Glucose, Humans, Hypertension, Obesity, Prediabetic State, United States, Dyslipidemias, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
